Why 4D Molecular Therapeutics, Inc.’s (FDMT) Stock Is Up 9.27%
As of Wednesday, August 19, 4D Molecular Therapeutics, Inc.’s FDMT share price has surged by 9.27%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Stock Evaluator: 4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. FDMT
$16.76
2.04
13.86%
August 19, 2026 4:00:00 PM
EST
Volume: 1,965,039
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Commentary & Analysis
Why 4D Molecular Therapeutics, Inc.’s (FDMT) Stock Is Up 13.57%
As of Wednesday, August 19, 4D Molecular Therapeutics, Inc.’s FDMT share price has surged by 13.57%, which has investors questioning if this is right time to sell.Jenna Brashear
Why 4D Molecular Therapeutics, Inc.’s (FDMT) Stock Is Up 5.07%
As of Monday, August 17, 4D Molecular Therapeutics, Inc.’s FDMT share price has surged by 5.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why 4D Molecular Therapeutics, Inc.’s (FDMT) Stock Is Up 14.81%
As of Monday, August 17, 4D Molecular Therapeutics, Inc.’s FDMT share price has surged by 14.81%, which has investors questioning if this is right time to sell.Tudor Pop
Is 4D Molecular Therapeutics, Inc. (FDMT) Overvalued?
We dive into why 4D Molecular Therapeutics, Inc. (FDMT) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Michael Rose
Financial Summary
| Share Statistics | FDMT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $925.9 | $289.8 | 44% |
|
| Shares Out (Mil) | 70.3 | 54.4 | 55% |
|
| Institutional Ownership | 96.0% | 92.8% | 69% |
|
| Float (Mil) | 42.4 | 39.7 | 44% |
|
| Beta | 2.69 | 0.93 | 97% |
|
| Avg Daily Volume (000s) | 1,169 | 524 | 73% |
|
| Price Change (52-week) |
130.5% | 60.8% | 94% |
|
| Growth | FDMT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 44.3% | 13.6% | 94% |
|
| Net Income (5yr) | (19.8%) | (10.1%) | 20% |
|
| EPS (5yr) | 22.8% | 16.0% | 72 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.4%) | (15.6%) | 49% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 9 | 9 | |
| Current EPS | ($1.043) | ($4.136) | ($4.087) | |
| Month Ago EPS | ($1.014) | ($3.926) | ($3.766) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($1.013) | ($4.030) | ($3.724) | |
| Year/Year Chg | 0.5% | 71.0% | 60.2% | |
| Financials | FDMT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $92 | $37 | 25% |
|
| Net Income (TTM) (Mil) | ($179) | ($43) | 7% |
|
| EPS (TTM) | ($2.774) | ($1.400) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($156) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $2 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $34 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $282 | $208 | 28% |
|
| Valuation | FDMT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.27 | 2.86 | 54% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FDMT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (157.7%) | 64.7% | 1% |
|
| Net Margin | (194.7%) | (75.9%) | 5% |
|
| ROA | (37.1%) | (47.6%) | 15% |
|
| ROE | (43.3%) | (54.1%) | 17% |
|
| Liabilities to Assets | 17.2% | 30.2% | 11% |
|
| F-Score | 3 | 2 | 18% |
|
Passing Stock Screens
As of 8/19/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
